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ANALISA VARIASI JUJUKAN DNA DI DALAM BAHAGIAN PERMULAAN 
GEN URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1 
(UGT1A1 ) DI KALANGAN BAYI KUNING TANPA VARIASI DI 
BAHAGIAN EXONIC 
 
ABSTRAK 
 
Pengeluaran bilirubin yang berlebihan merupakan salah satu faktor yang 
menyebabkan demam kuning dalam kalangan bayi baru lahir dan proses ini 
dimangkinkan oleh sejenis enzim iaitu Uridine glucuronosyltransferase yang 
dikodkan oleh gen UGT1A1 dan ini adalah suatu keadaan yang lazim berlaku selepas 
lahir. Objektif kajian ini adalah untuk mengesan kehadiran mutasi pada bahagian 
permulaan gen UGT1A1 dalam kalangan bayi Melayu yang menghidap demam 
kuning dan tanpa demam kuning dengan menggunakan kaedah analisis resolusi 
tinggi lebur (HRM) dan untuk mencari hubungkait antara mutasi-mutasi yang 
dikenal pasti dengan menggunakan analisis ketidakseimbangan. Semua sampel yang 
bebas dari mutasi pada bahagian ekson telah diambil daripada sambungan kajian Nur 
Hasnah Ma’amor. Analisis HRM dilakukan bagi menyaring bahagian permulaan gen 
UGT1A1 gene dan subjek yang dikenal pasti mengandungi bentuk yang berbeza 
semasa analisis HRM akan menjalani  proses penjujukan DNA bagi mengesahkan 
kehadiran mutasi. Data dianalisa dengan menggunakan SPSS program. Seramai 250 
bayi yang menjalani fototerapi dikategorikan sebagai kumpulan bayi kuning dan 
seramai 260 bayi yang tidak melalui fototerapi dikategorikan sebagai bayi normal. 
Enam mutasi telah dianalisis dalam kajian ini dan dua mutasi tidak berjaya ditemui 
xix 
 
dalam populasi Melayu. Mutasi yang paling kerap adalah c.-3279T>G yang terletak 
pada bahagian permulaan gen UGT1A1. Semua mutasi ini pernah dilaporkan dalam 
populasi India, Caucasian dan Jepun. Seramai 163 pesakit mempunyai variasi c.-
3279T>G telah dikenal pasti dengan nilai p=0.001 dan ianya merupakan faktor 
berlakunya demam kuning di kalangan bayi Melayu.  
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ANALYSIS OF NUCLEOTIDE VARIANTS IN THE PROMOTER REGION 
OF THE URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1 
(UGT1A1 ) GENE AMONG NEONATAL JAUNDICE MALAY INFANTS 
WITHOUT VARIANTS IN THE EXONIC REGIONS 
 
ABSTRACT 
 
Overproduction of bilirubin is one of the major factor which contributes to neonatal 
hyperbilirubinemia that is catalyzed by an enzyme Uridine glucuronyl transferase 
encoded by the UGT1A1 gene. This is a normal physiological occurance after birth.  
The objectives of this study were to i) determine the presence of variants or 
polymorphisms in the promoter region of the UGT1A1 gene amongst Malay infants 
with and without jaundice using high resolution melting (HRM) analysis and to 
assess the correlation between identified variants or polymorphisms using linkage 
disequilibrium analysis. All samples that were free from variant in the exonic regions 
were recruited from another study by Hasnah Ma’amor in year 2011. High resolution 
melting analysis was performed to screen for the promoter region in the UGT1A1 
gene and for subjects who were identified to have different pattern of HRM analysis, 
sequencing was performed to confirm the presence of variant. SPSS was used for 
data analysis. Two hundred and fifty (250) infants who were undergone phototherapy 
and 260 infants who were not undergoing phototherapy were included in the 
jaundiced and non-jaundice groups. Six variants were investigated but two were not 
detected in this study. The most common variant was c.-3279T>G which is common 
in other Asian populations as well. All the variants detected in this study have been 
xxi 
 
reported as SNPs in Indian, Caucasion and Japanese populations. The c.-3279T>G 
variant had been identified as the most common variant in 163 jaundice Malay 
patientsin the promoter region of the UGT1A1 gene with the p-value 0.001 and is a 
risk factor for Malay neonatal hyperbilirubinemia. 
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CHAPTER 1 
 
 INTRODUCTION 
1.1 Neonatal hyperbilirubinemia 
Neonatal hyperbilirubinemia is a normal physiological condition after birth 
and is a major concern for paediatricians and parents. This phenomenon  is related to 
the  deposition of serum bilirubin in the tissue leading to yellow discoloration of 
skin, mucosal  membranes and sclera in newborn neonates. 
According to Maisels 1988, this phenomenon occurs in 60% of full term 
infants and 80% of premature infants (Maisels et al., 1988). Based on a study in 
2002, the peak serum bilirubin level among  full term Asian (Japanese, Korean and 
Chinese) population are double compared to the Caucasian and Black population 
(Avery, 1981; Avery et al., 2005). In addition to this, the frequency and severity of 
neonatal jaundice in Asians are higher compared to Caucasians, including the 
incidence of kernicterus (Avery, 1981; Fischer et al., 1988; Setia et al., 2002). 
The incidence of neonatal hyperbilirubinemia is also significantly higher in 
African population compared to American population with an African ancestry 
(Kaplan et al., 2008). Previous studies reported that neonatal jaundice is associated 
with both environmental and genetic factors (Kaplan and Hammerman, 2005; 
Behjati-Ardakani and Sedaghat, 2007). 
 In Malaysia, cord blood sampling of infants are screened for haemolysis sign 
and ABO incompatibility (Fabris et al., 2009). According to Bosma 1995, variants in 
UGT1A1 gene play a critical role towards the development of neonatal jaundice such 
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as the A(TA)7TAA in the promoter region. In 1995, a study reported that variants in 
the Uridine Diphosphate Glucuronosyltransferase 1A1 (UGT1A1) gene is a potential 
as a genetic risk factor for neonatal hyperbilirubinemia (Bosma et al., 1995). For 
instance, serum bilirubin levels in Japanese newborns were higher as compared to 
Caucasian newborn infants due to different genetic background between populations 
(Fischer et al., 1988). 
1.2 Uridine Diphosphoglucuronate Glucuronosyltransferase (UDPGT) 1A1 gene 
 The entire structure of  uridine diphosphoglucuronate glucuronosyltransferase 
1A1 (UGT1A1) gene was first reported in 2001 (Gong et al., 2001). Van Es et al 
found that the UGT1A1 gene complex is located on chromosome 2q37 (Figure 
1.1)(Van Es et al., 1993). The length of this gene is 218 kb. It consists of 13 amino 
terminal exons and four common carboxy terminal exons. The amino terminal exons 
are responsible to encode the substrate binding domain where as the carboxy 
terminal exons are responsible to encode the UDP glucuronic acid binding and 
membrane spanning region. The presence of variants in this gene results in a 
frameshift or a premature stop codon and produce non-functional protein (Bosma, 
2003). 
This gene is responsible for the production of the enzyme bilirubin uridine 
diphosphate glucuronosyltransferase (B-UGT) that is important in glucuronidation 
activity (Ritter et al., 1991). Polymorphisms  in  the exons and promoter region of 
the UGT1A1 gene will cause structural or functional abnormalities of the enzyme 
which leads to non-hemolytic unconjugated hyperbilirubinemia (Kaplan et al., 2003). 
Crigler Najjar syndrome type 1 (CN-I, a severe form), Crigler Najjar syndrome type 
2 (CN-II, an intermediate form) and Gilbert syndrome (GS, a mild form) is 
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associated with variants in the UGT1A1gene, based on clinical severity (Seppen et 
al., 1994; Kadakol et al., 2000). 
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Figure 1.1: Location of the UGT1A1 gene in chromosome 2(2q37.1) 
:http://asia.ensembl.org/Homo_sapiens/Location/Chromosome?R=2:2346693
368-234682419;g=ENSG00000241625;r=2:226432585-
226432874;t=ENST00000466851 
 
 
Location of UGT1A1 gene 
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Figure 1.2: Sites for human uridine diphosphate glucuronosyltransferase-1 gene (UGT1). 
UDPGA, uridine diphosphate glucuronic acid binding site and membrane spaning region. 
Gourley  GR. Neonatal jaundice and disorder of bilirubin metabolism. Suchy FJ, 
Sokol RJ, BalisteriWF [Eds]. Liver disease in children, 3
rd
ed. New York, Cambridge 
University Press, 2007 
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Liver is the major organ that is responsible for glucuronidation during the 
oral absorption of drug in the body (Tukey and Strassburg, 2000; Fisher et al., 2001; 
Strassburg, 2008). In human, bilirubin molecule is one ofthe endogenous substrates 
that is selectively glucuronidated by the superfamily of enzymes human UGTs of 
UGT1A1 gene. Whereas drugs, environmental pollutants, chemical carcinogen and 
dietary substances are examples of exogenous substrates for human UGT (Tukey and 
Strassburg, 2000)(Ritter, 2000). 
 The exogenous substrates such as drug molecules are hydrophilic and easily 
excreted (Ouzzine et al., 2003). In the glucuronidation reaction, UDP glucuronic acid 
is converted to hydrophobic drug molecules to form β-D-glucuronides which 
comprise of functional group; that consist of aromatic, aliphatic alcohols, carboxylic 
acid, amines and free sulfhydryl moiety (King et al., 2000, Guilemette, 2003). 
Variant of A(TA)7TAA located in the promoter region of the UGT1A1 gene is one of 
the commonest genetic polymorphism associated with Gilbert syndrome in 
Caucasian population. Previous studies suggested that the UGT1A1 gene is 
responsible for glucuronidation activity in the bilirubin metabolism pathway (Miners 
et al., 2002; Burchell, 2003).  
The A(TA)7TAA variant is associated with the reduction and elimination of 
active metabolite of irrinotecan, SN-38 (Ando et al., 2000, 2002; Iyer et al., 2002). A 
study in 2004 suggested that, variants of A(TA)7TAA may result in drug toxicity. 
The detection of this variant, facilitates the use of alternative therapy in reducing the 
incidence of irrinotecan toxicity (Marsh & McLeod, 2004). In other studies, it was 
suggested that, Crigler Najjar syndrome patients are associated with homozygous 
variant in the TATA box in the promoter region of the UGT1A1 gene (Kearns et al., 
1985; Bosma 2003). 
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Based on Innocenti et al in 2005, they found that variant TATA box, 
c.211G>A and c.-3279T>G are the three major variants with different prevalence in 
various population. In year 1993, Van Es et al showed that variant TATA box was 
found in patient with Crigler Najjar type II and Gilbert syndrome. It is located in the 
proximal promoter region which the variant consist of an additional TA insertion, 
A(TA)7TAA. A few years later, Ciotti et al showed that the variant TATA box is 
also found in Crigler Najjar syndrome type I (Ciotti et al., 1998).  
The development of Gilbert’s syndrome is not entirely dependent on the  
A(TA)7TAA variant. For example, homozygosity of A(TA)7TAA in most Gilbert 
syndrome patients may occur in combination homozygosity of the other variant, c.-
3279T>G (Maruo et al., 2004; Costa et al., 2005; Ferraris et al., 2006). 
 The 2-bp addition in the TATA box promoter region was reported to reduce 
the UGT1A1 gene expression level of UGT1A1 gene in Gilbert syndrome patients by 
25 to 50% of normal (Bosma et al., 1995; Monaghan et al., 1996a). A few years later, 
Bancroff and Monaghan discovered that homozygosity of A(TA)7TAA can 
accelerate neonatal jaundice (Monaghan et al., 1996b; Bancroft et al., 1998). 
 Other than A(TA)7TAA, there are two types of polymorphic variants in the 
UGT1A1 promoter region which are c.-3279T>G and c.-3156G>A. The c.-3279T>G 
variant is located in phenobarbital responsive enhancer module (gtPBREM) 
(Sugatani et al., 2001) and was postulated to reduce the responsiveness of UGT1A1 
transcription to bilirubin (Yusoff et al., 2010). It reduced 60% activity of UGT1A1 
promoter and was suggested as a genetic risk factor for neonatal jaundice (Sugatani 
et al., 2002; Yusoff et al., 2010) 
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1.3 Gilbert syndrome 
 Gilbert syndrome is caused by variants in the UGT1A1 gene. In Gilbert 
syndrome patients, the hepatic activity of bilirubin  glucuronosyltransferase is 
decreased to 30% of normal which can reduce the percentage of bilirubin 
diglucuronides in bile (Arias and London, 1957; Black and Billing, 1969; Fevery et 
al., 1977). The genetic basis of the reduction of bilirubin glucuronidation was 
discovered by Bosma in 1995 (Bosma et al., 1995) and varied between different 
population (Beutler et al., 1998; Hall et al., 1999). 
According to previous studies, the percentage of Gilbert syndrome in 
Caucasian population was 5 to 10%  and is a common disorder (Owens and Evans, 
1975; Sieg A, 1987). In this population, the bilirubin glucuronidation activity was 
reduced by 80% in patients who were homozygous variant  for TA  insertion in 
TATA box in the proximal promoter of the UGT1A1 gene (Bosma, 2003). The 
efficiency of transcription of the UGT1A1 gene is reduced when the expanded 
element seven TA repeats were present. According to previous data, increasing 
number of TA repeats leads to decreasing transcriptional activity in the UGT1A1 
gene promoter (Iolascon et al., 1999). This report was supported by Bosma and 
Monaghan that homozygosity of A(TA)7TAA in Gilbert syndrome can  reduce the 
expression level  activity of the UGT1A1 gene.   
Gilbert syndrome affects 6 to 12% of individuals which their range of serum 
bilirubin levels is between 52 and 86 μmol/L. When the serum bilirubin level in 
patients with Gilbert syndrome is increased, it can cause reduction in hepatic activity 
of bilirubin glucuronsyltransferase (Arias and London, 1957; Black and Billing, 
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1969). Previous studies suggested that most of heterozygous missense variants of 
UGT1A1 gene were related to A(TA)7TAA variant.  
1.4 Crigler Najjar syndrome 
 In 1992 and 1993, the first variant causing Crigler Najjar syndrome type I and 
type II were discovered (Bosma et al., 1992; Ritter et al., 1992; Bosma PJ, 1993). 
The frequency of this syndrome is very rare which is 0.6 per million (van der Veere 
et al., 1996). Crigler Najjar syndrome is a type of UGT1A1 enzyme deficiency 
syndrome. It can be divided into two types which is type I and type II. Crigler Najjar 
type I (severe phenotype) and type II (intermediate phenotype) is the result from 
complete and partial deficiencies of UGT1A1 gene activity (Owens and Evans, 
1975). Some of Crigler Najjar syndrome  relatives have mild form unconjugated 
hyperbilirubinemia has been reported in 1962 (Arias, 1962). 
Phenobarbital treatment was suggested to cause 30% reduction of serum 
bilirubin level in CN type II but no minor effect is observed in CN type I. The traces 
of bilirubin glucuronides for CN type I patient was absent and it was present in CN 
type II patient. The presence of bilirubin glucuronides in bile indicate bilirubin 
glucuronidating activity. Some of CN type II patients have died due to kernicterus 
(chronic bilirubin intoxication in the brain) but most will survive until adulthood.  
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Diagnosis of neonatal jaundice 
 Gilbert syndrome Crigler Najjar 
Syndrome type 
I 
Crigler Najjar 
syndrome type 
II 
Prevalence 3% rare rare 
Inheritance Autosomal dominant or 
recessive 
Autosomal 
resessive 
Autosomal 
recessive,rarely 
dominant 
Genetic Defect UGT1A1 gene UGT1A1 gene UGT1A1 gene 
Hepatocyte defect site Microsomes±plasma 
membrane 
Microsomes Microsomes 
Deficient hepatocyte function Glucuronidation±uptake Glucuronidation Glucuronidation 
BUGT activity 5-53% of controls Severely 
decrease 
2-23% of 
controls 
Total serum bilirubin levels (mg/dL) 0.8-4.3 15-45 8-25 
Serum bilirubin decrease with 
Phenobarbital(%) 
70 0 77 
Bile bilirubin conjugates 
Diglucuronide(normal~80) 60 0 to trace 5-10 
Monoglucuronide(normal~15) 30 Predominant if 
measurable 
90-95 
Prognosis Benign Kernicterus 
common 
Occasional 
kernicterus 
Table 1.1: Comparison disorder of unconjugated hyperbilirubinemia.Gourley GR. Neonatal 
jaundice and disorder of bilirubin metabolism. Suchy FJ, Sokol RJ, BalisteriWF[Eds]. Liver 
disease in children, 3rd ed. New York, Cambridge University Press, 2007 
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1.5 Bilirubin Uridine Diphosphate Glucuronosyltransferase (B-UDPGT)  
Bilirubin uridine diphosphate glucuronosyltransferase (B-UDPGT) enzyme is 
the catalyst that is responsible for bilirubin glucuronidation pathway. Its deficiency 
can lead to unconjugated hyperbilirubinemia (Bosma et al., 1994). The percentage of 
activity towards bilirubin changes with age. These enzyme activity is shown as 0.1 in 
middle fetal, 0.1 to 1 during neonatal and 1 to 100% in early infatile respectively, by 
refering with mature phase values, (Kawade and Onishi, 1981). The  bilirubin levels 
also correlate with the frequency of different variants either in the promoter or 
coding regions of the UGT1A1 gene (Huang et al., 2000). B-UDPGT is encoded by 5 
exons including 1A1, 2, 3, 4 and 5 at the UGT1A locus (Van Es et al., 1993). 
According to a report in the year 2003, the nomenclature of UGT1A is based on 5 
respective exons (Mackenzie et al., 2003). The 4 common exons are involved in the 
co-substrate and substrate binding domain due to C-terminal and N-terminal portion 
of the enzyme (King et al., 2000). The UGT1A gene locus contains 12 variable exons 
(A2-A13) that are responsible to encode other UDPGT isoform (Clarke et al., 1997). 
Bilirubin is the product from heme catabolism. Heme is found from 
hemeproteins, haemoglobin, cytochromes, catalase and peroxidase. Bilirubin is 
changed to bilirubin glucuronic acid in the liver and will be excreted in bile (Bosma, 
2003). There are two kinds of bilirubin in man which is direct reacting bilirubin and 
indirect reacting bilirubin.  
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1.51 Indirect Hyperbilirubinemia (Unconjugated Bilirubin) 
Unconjugated bilirubin causes indirect hyperbilirubinemia. It occurs when the 
serum bilirubin level is greater than 34.2µmol/L and it consists of lipid soluble 
molecule. With these, bilirubin is able to accumulate in certain parts of the body. 
Only a small fraction of unconjugated bilirubin that is unbound to albumin can enter 
the brain.  Accumulation of  bilirubin in the brain may cause neurological disease 
and kernicterus. It occurs due to the ability of bilirubin to cross the blood brain 
barrier (Juretschke, 2005). The presence of endogenous or exogenous binding 
competitors compound such as drug towards albumin decreases the binding affinity 
of albumin resulting in kernicterus. 
1.52 Direct Hyperbilirubinemia (Conjugated Bilirubin) 
Direct hyperbilirubinemia is caused by conjugated bilirubin. Conjugated 
bilirubin is water soluble molecules that are able to move from the bile duct to the 
intestine (Odell, 1980). This conjugation process is catalysed by uridine 
glucuronosyltransferase (UGT). According to Klein, hepatocellular disease and 
metabolic disorder are general factors for direct hyperbilirubinemia in the neonates 
(Klein et al., 2010). 
 Due to erythrocyte cycles, bilirubin is produced at 250mg/day. This 
mechanism is potentially associated with jaundice and hyperbilirubinemia (Chodhury 
R et al., 1995). In human, bilirubin diglucuronide is catalyzed by bilirubin UDP-
glucuronosyltransferase in hepatic endoplasmic reticulum and efficiently transported 
into the liver because of more polar water soluble of  bilirubin diglucuronide. It is 
then excreted into the bile via membrane in the bile canaliculus (Clark D J et al., 
1997). 
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1.53 Redox cycle 
 Heme oxygenase and biliverdin reductase consist of reducing properties that 
are responsible for degradation of heme and reduction of bilirubin. Bilirubin has 
antioxidant potential especially in blood plasma, as demonstrated by many chemical 
and biochemical in vitro studies and it can protect the cell from oxidative damage. 
However, this hypothesis  remains unclear. Redox cycle is the famous explanation 
for antioxidant properties for bilirubin. These cycles showed that biliverdin were 
recycled by bilirubin reductase following oxidation by bilirubin (Maghzal G J et al., 
2009). This enzyme has an important role against H2O2-mediated oxidative stress 
through redox amplification cycle (Sedlak T W et al., 2004). Redox cycle occurs in 
the presence of the ubiquitous of biliverdin reductase (Maghzal et al., 2009). In the 
presence of intramolecular hydrogen bonding inside the bilirubin molecules, it 
became soluble in water at physiological pH and ionic strength (McDonagh et al., 
1979). 
 These hydrogen bond exist when bilirubin is combined with cell membrane 
(Nogales D et al., 1995). Before the uptake of bilirubin by hepatocytes, it is closely 
bound to albumin and will be circulated within the blood (Brodersen et al., 1980). 
Inside the hepatocytes, bilirubin molecules are attached with glutathione S-
transferases before being converted to water soluble derivatives. This process 
involves conjugation of one or both of its propionyl groups before its discharge into 
bile and the intestine (Fevery Jet al., 1977). When the molecule of bilirubin is 
attached to the primary site  of albumin, it were leading to formation of two planar 
dipyrroles involve ion pairing, hydrogen bonding and π interaction out of plane 
position and leading to break up its intramolecular hydrogen bond ( Hsieh Y Z 1988). 
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Conjugated bilirubin is hydrophilic which is easier to be excreted into bile. In 
the absence of these enzyme, bilirubin cannot be excreted rapidly by the liver. In 
these cases, serum bilirubin will increase and bilirubin molecules is deposited in the 
body tissue leading to neonatal hyperbilirubinemia.  Unconjugated bilirubin in the 
serum may cross the blood brain barrier (BBB) and take them at risk of developing 
bilirubin encephalopathy (acute bilirubin intoxication in the brain) or kernicterus 
(chronic bilirubin intoxication in the brain) Bhutani and Johnson, 2005; Morioka., 
2010). The complete scheme of the biosynthesis of bilirubin is shown in Figure 1.3. 
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Fig. 1.3: The complete scheme of the stereochemistry biosynthesis of bilirubin metabolism. The 
production of bilirubin from heme catalyse by heme-oxygenase and subsequently 
biliverdinreductase. Glucuronidation of bilirubin by UDP-glucuronosyltransferaseUGT1A1 
results in the formation of bilirubin mono- and di-glucuronide which are excreted into bile. The 
figure was adapted from Bosma, 2003 
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1.6 Mechanism of Phototherapy 
Phototherapy is an effective treatment in infants to decrease the concentration 
of circulating bilirubin level. It has been used as a method of treating neonatal 
hyperbilirubinemia because of the effectiveness of light and its ability to reduce 
serum bilirubin during  phototherapy (Maisels and McDonagh., 2008). A previous 
study suggested that intensive phototherapy is able to reduce 10mg per decilitre of 
serum bilirubin levels within a few hours in infants who have serum bilirubin levels 
greater than 30mg per decilitre (Hansen, 1997). Phototherapy refers to the use of 
light to convert bilirubin molecules in the body into water soluble isomers that can be 
excreted by the body. This treatment is effective due to the ability of blue light to 
break the internal Hydrogen bonds in unconjugated bilirubin molecules namely 
photoisomer. The product forms are hydrophilic molecules that are soluble in water 
which can be excreted in bile (Van der Veere et al., 1997). 
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Figure 1.4: Biological pathway of normal bilirubin metabolism with and without phototherapy 
(Maisels and McDonagh, 2008) 
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This mechanism is effective because three reactions can occur when bilirubin 
is exposed to light. Absorption of light by the dermis will change the normal 
structure of bilirubin form 4Z, 15Z-bilirubin into 2 isomeric forms: structural and 
configurational isomer. Both Z and E configurationsand prefixes 4 and 15 are used to 
indicate the stereochemistry and position of double bond respectively (McDonagh, 
1986). 
The main structural isomer of bilirubin is Z-lumirubin and the main 
configurational isomer of bilirubin is 4Z, 15E –bilirubin. Configurational isomer is 
reversible but structural isomer is irreversible. Both photo isomers are less lipophilic 
than normal bilirubin and can be excreted into bile without undergoing 
glucuronidation in the liver. Some of the configurational isomers of bilirubin revert 
spontaneously to the parent form isomer after excretion into bile and can be 
reabsorbed via the enterohepatic circulation in the gut. Structural bilirubin isomers, 
consist of  intramolecular cyclization resulting  in Z-lumirubin, which can also be 
excreted in the urine. 
 The absorption of light by normal form bilirubin also results in the 
generation of excited-state bilirubin molecules that react with oxygen to produce 
colourless oxidation products. This process occurs more slowly than configurational 
or structural isomerization. The figure 1.5 below provides a schematic of the 
conversion of normal bilirubin to configurational isomers, structural isomers and 
photooxidation products and the respective routes of excretion from the body 
(McDonagh, 1986). 
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Figure  1.5: Mechanism absorption of light by normal form of bilirubin (McDonagh, 1986) 
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Figure 1.6: The stereochemistry of  2 isomeric form; structural and configurational isomer 
structure when absorbtion of light by dermal surface.Taken from: Gourley GR. Neonatal 
jaundice and disorder of bilirubin metabolism.Suchy FJ, Sokol RJ, BalisteriWF[Eds]. Liver 
disease in children, 3rd ed. New York, Cambridge University Press, 2007 
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In phototherapy, blue-green light mechanism in the range of 460-490 nm is 
the most effective for treating hyperbilirubinaemia. The absorption of light by one or 
both of the propionic acid side chains in the normal bilirubin (4Z, 15Z-bilirubin) can 
increase the polarities which generates configuration isomers, structural isomers, and 
photooxidation products. The two principal photoisomers formed in human are 
shown in Figure 1.5. Photooxidation occurs more slowly than configurational and 
structural isomerization. Photooxidation and photoisomer products are primarily 
excreted in the urine and bile (Maisels and McDonagh, 2008). 
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Figure 1.7: Bilirubin diglucuronide. In bilirubin monoglucuronide, only one propionic acid side 
chain (C-8 or c-12) is glucuronidated. Taken from: Gourley GR. Neonatal jaundice and disorder 
of bilirubin metabolism. Suchy FJ, Sokol RJ, BalisteriWF[Eds]. Liver disease in children, 3rd 
ed. New York, Cambridge University Press, 2007 
 
 
 
 
Propionic acid side chains 
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1.7 Bilirubin metabolism 
Bilirubin is the oxidative product that is produced by catabolism of 
hemoglobin. Hemoglobin is the largest source of bilirubin production. The 
hemoglobin catabolism and bilirubin production are higher in newborn neonates 
compared to older children and adults due to shorter life span of red blood cells of 70 
to 90 days. The bilirubin clearance is delayed if there is immaturity of hepatic 
glucuronosyltransferase and inadequate milk intake (Moerschel et al., 2008). More 
than 80% of the bilirubin  produced is derived from heme catabolism of senescent 
red blood cells (RBC) and the remaining are derived from other hemoproteins such 
as myoglobin and cytochrome P-450 (Kaplan and Hammerman, 2005). In the initial 
stage, bilirubin is in the unconjugated form and is lipid soluble. This molecule enters 
the serum and is transported to the liver and binds to albumin (Moerschel et al., 
2008). According to Kaplan 2005, sufficient serum albumin should be available with 
the amount of bilirubin produced under physiological conditions and unbound 
bilirubin freely accumulates in the serum. Conjugated molecule of bilirubin albumin 
in the newborn babies against bilirubin encephalopathy. 
The production of  bilirubin, it is started by heme oxygenase which is 
involved in the heme catabolism in mammalian cells. In the reticuloendothelial 
system, heme is broken down into biliverdin and latter subsequently metabolized to 
bilirubin. These process are catalyzed by enzymes hemeoxygenase and bilirubin 
reductase. For each molecule of bilirubin derived by this process, equimolar 
quantities of carbon monoxide (CO) are being produced. These CO molecule binds 
to hemoglobin to form carboxyhemoglobin (COHb) which it is transported to the 
lungs and exhaled (Bosma, 2003). Biliverdin produced will be converted to bilirubin 
by catalytic enzyme, biliverdin reductase in the presence of NADPH. Elevation 
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yields of biliverdin are limited in certain oxidants such as peroxyl radical and 
albumin bound bilirubin (Maghzal et al., 2009).  
Unconjugated bilirubin is an organic anion and toxic to the central nervous 
system and it cannot be excreted in this form (Kaplan and Hammerman, 2005; 
Moerschel et al., 2008). To begin the excretion process, unconjugated bilirubin is 
taken up by hepatocyte. Unconjugated bilirubin is conjugated into glucuronic acid 
which is water soluble and easily excreted by the liver and biliary tract. This process 
is catalyzed by enzyme uridine diphosphoglucuronate glucuronosyltransferase 1A1 
(UGT1A1). Monoglucuronide and diglucuronide fractions are the identified form of 
conjugated bilirubin fraction.  For monoglucuronide fraction, bilirubin reacts with 
one glucuronic acid whereby for diglucuronide fraction bilirubin reacts with two 
glucuronic acids. Both fraction product are excretable and most are converted to non-
reabsorble products and  excreted in the stool (Kaplan and Hammerman, 2005). 
 Based on Sarah and co-workers, bilirubin will be reabsorbed by the intestine 
if it is converted back into the unconjugated form. In the breastfed neonates, the 
mucosal enzyme β-glucuronidase can cleave off the conjugated bilirubin molecule 
resulting in unconjugated bilirubin molecule to be reabsorbed, re-entering the 
bilirubin pool and loaded on the hepatocyte. This is known as the enterohepatic 
bilirubin circulation. 
Biliverdin is a linear tetrapyrole form  and the product of protoporphyrin 
(tetrapyrrole ring of protoheme) in the rate limiting step that is catalysed by 
microsomal hemeoxygenase enzyme (Ryter et al., 2006). HO consists of two major 
form, inducible form (HO1) and constitutive form (HO2). HO1 is located in the 
spleen, liver and bone marrow and HO2 is located in the testes, central nervous 
